This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/US Food and Drug Administration–sponsored Think Tank Meeting on May 22, 2018. The meeting was convened to evaluate the progress in the development of a new cardiac safety paradigm, the Comprehensive in Vitro Proarrhythmia Assay (CiPA). The opinions regarding these principles reflect the collective views of those who participated in the discussion of this topic both at and after the breakout session. Although primarily discussed in the context of in silico models, these principles describe the interface between experimental input and model-based interpretation and are intended to be general enough to be applied to other types of nonclinical models for proarrhythmia assessment. This document was developed with the intention of providing a foundation for more consistency and harmonization in developing and validating different models for proarrhythmia risk prediction using the example of the CiPA paradigm.

Li, Z., Mirams, G.R., Yoshinaga, T., Ridder, B.J., Han, X., Chen, J.E., et al. (2020). General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107(1), 102-111 [10.1002/cpt.1647].

General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy

Severi S.;
2020

Abstract

This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/US Food and Drug Administration–sponsored Think Tank Meeting on May 22, 2018. The meeting was convened to evaluate the progress in the development of a new cardiac safety paradigm, the Comprehensive in Vitro Proarrhythmia Assay (CiPA). The opinions regarding these principles reflect the collective views of those who participated in the discussion of this topic both at and after the breakout session. Although primarily discussed in the context of in silico models, these principles describe the interface between experimental input and model-based interpretation and are intended to be general enough to be applied to other types of nonclinical models for proarrhythmia assessment. This document was developed with the intention of providing a foundation for more consistency and harmonization in developing and validating different models for proarrhythmia risk prediction using the example of the CiPA paradigm.
2020
Li, Z., Mirams, G.R., Yoshinaga, T., Ridder, B.J., Han, X., Chen, J.E., et al. (2020). General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107(1), 102-111 [10.1002/cpt.1647].
Li, Z.; Mirams, G. R.; Yoshinaga, T.; Ridder, B. J.; Han, X.; Chen, J. E.; Stockbridge, N. L.; Wisialowski, T. A.; Damiano, B.; Severi, S.; Morissette...espandi
File in questo prodotto:
File Dimensione Formato  
Clin Pharma and Therapeutics - 2019 - Li - General Principles for the Validation of Proarrhythmia Risk Prediction Models .pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 431.34 kB
Formato Adobe PDF
431.34 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/714797
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 59
social impact